Forero-Torres, A., Varley, K. E., Abramson, V. G., Li, Y., Vaklavas, C., Lin, N. U., . . . Wolff, A. C. (2015). TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC or Abraxane®) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer. Clin Cancer Res.
Citação norma ChicagoForero-Torres, Andres, et al. "TBCRC 019: An Open Label, Randomized, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (nab-PAC or Abraxane®) With or Without the Anti-death Receptor 5 (DR5) Monoclonal Antibody Tigatuzumab in Patients With Metastatic Triple Negative Breast Cancer." Clin Cancer Res 2015.
Citação norma MLAForero-Torres, Andres, et al. "TBCRC 019: An Open Label, Randomized, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (nab-PAC or Abraxane®) With or Without the Anti-death Receptor 5 (DR5) Monoclonal Antibody Tigatuzumab in Patients With Metastatic Triple Negative Breast Cancer." Clin Cancer Res 2015.